My confidence is not swayed by the daily trading swings or by the ignorant who post on message boards, like the poster I responded to. Set your goals and stand by them.
In fact, you probably can't afford to be in this stock and should find somewhere else to play it safe. Please don't read my posts, in the future. Thank you.
March 23, 2015 08:00 AM Eastern Daylight Time
SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ:CYTX) will present data from two preclinical studies describing safety and efficacy of ADRCs for treatment of thermal burn injuries at the Annual Meeting of the American Burn Association (ABA) in Chicago on April 21-24, 2015. This research, funded by the contract with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services, was part of the package of data submitted to the US Government as part of the In-Process Review meeting that led to the execution of the current contract option valued at $14.1 million, and part of Cytori’s $106 million BARDA contract framework.
“These are encouraging data that support the advancement of Cytori Cell Therapy to accelerate wound healing in severe burn patients”
The first presentation will describe the use of Cytori Cell Therapy in combination with a widely used skin substitute in a full thickness burn injury model. Data to be presented show increased wound vascularity and maturation in wounds treated with Cytori Cell Therapy. The second presentation will describe a novel model of full thickness thermal burn injury with concomitant radiation exposure. Data to be presented demonstrate that delivery of Cytori Cell Therapy accelerates wound re-epithelialization in this context. These data will form the basis of an Investigational Device Exemption (IDE) package to be submitted to FDA for a proposed clinical trial using Cytori Cell Therapy in thermal burn injury.
Interest is growing.
You will understand what all the excitement is about.
So if you were one of those patients who have experienced great relief and improvement from a terrible condition due to the trial, would you still think it is all fluff?
Yes, that is true. Thank you for the rational view.
the share value sure does impede capital for advancement. Why can't these folks trade without trying to gain an advantage by using lies and deceit?
for mankind by their trading tactics just for a short term gain.
Do a google search on KT he is Big Time.
Mr. Kian Thiam Lim is the Founder Victoria Investments & Properties Pty, Ltd. and Jayaland Corporation Pty Ltd and has been its Chairman, since 1994. Mr. Lim serves as a director of a number of private companies in Malaysia and Australia, which are involved in property investment. He served as a Non-Independent Non-Executive Director of Axis Reit Managers Bhd., from March 15, 2005 to August 10, 2007. Mr. Lim is a member of the Malaysian Institute of Certified Public Accountants since 1978 and has been a Council Member since 1988.
PRECISE Data Demonstrate Sustained Safety and Benefit at 18-Months
SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics (NASDAQ: CYTX) today announced publication of safety and efficacy data from a 36 month European clinical trial of Cytori Cell Therapy in patients with chronic ischemic heart failure. Final data from the Company’s PRECISE trial, a 27-patient, prospective, randomized, double-blind, placebo-controlled, feasibility trial (Phase I/IIA), demonstrated statistically significant differences in cardiac functional capacity between treated and placebo groups and will appear in an upcoming issue of the American Heart Journal. Cytori Cell Therapy is a mixed population of adipose derived regenerative cells (ADRCs™) extracted from a patient’s own adipose tissue using Cytori’s proprietary Celution® System.
First Patient Treated in Cytori’s U.S. Cell Therapy Heart Failure TrialSystem
Adipose-Derived Regenerative Cells Improve Cardiac Functional Capacity at 18 Months in Chronic Ischemic Heart Disease Patients
Cytori Reports Stem & Regenerative Cells from Body Fat Produce Statistically Significant Improvement in Heart Function in Chronic Ischemia Trial
“The PRECISE trial is the first-in-man trial involving the myocardial injection of ADRCs for heart disease,” said Dr. Emerson Perin , Co-Principal Investigator of the trial. “By demonstrating a strong safety profile and suggesting that the use of ADRCs may preserve functional capacity, the data indicates that this therapy may have meaningful impacts on the lives of these very sick patients.”
In a report published Wednesday, Maxim Group analyst Jason Kolbert discussed Cytori Therapeutics Inc (NASDAQ: CYTX)'s announcement earlier this week that the European Medicines Agency Committee for Orphan Medicinal Products has designed Cytori's ECC S-50 cellular therapeutic as an orphan medicinal product for the treatment of scleroderma.
Kolbert noted that the regulatory clearance officially makes Cytori's Celution System available in the largest healthcare market in the world and triggers a "substantial" 2015 product purchase order for Cytori from Lorem Vascular Pte. Ltd.
Meanwhile, Cytori is about to begin a phase 3 clinical trial in the U.S. with the same product in up to 20 sites. Kolbert stated that the clinical data could also be used to support regulatory approvals and reimbursement in the European Union as well as other global markets.
Shares remain Buy rated with a $7 price target.
Cytori Therapeutics, Inc. (CYTX) announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products, has designated Cytori’s ECCS-50 cellular therapeutic as an orphan medicinal product for the treatment of scleroderma. This designation marks the first autologous adipose derived cell therapy for scleroderma granted orphan status in the European Union (EU)
They should be sued for libel and damages.
So we will see who has that LAST LAUGH :) Thanks for the shts and giggles
and will continue to do so as this company finally emerges as a real player on the global stage.